M&A

News

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.

News

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

News

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

News

Gilead strikes again, penning $5bn deal to buy Tubulis

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

News

AI giant Anthropic buys Coefficient Bio for $400m

Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio.

News

Neurocrine pays $2.9bn for Soleno and extreme hunger drug

Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.

Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia

UCB cuts $1.15bn deal to buy epilepsy biotech Neurona

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Gilead strikes again, penning $5bn deal to buy Tubulis

AI giant Anthropic buys Coefficient Bio for $400m

Neurocrine pays $2.9bn for Soleno and extreme hunger drug

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks